S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.97 (+1.23%)
AAPL   143.14 (+1.56%)
MSFT   246.59 (+0.91%)
META   115.76 (+1.61%)
GOOGL   94.11 (-0.87%)
AMZN   90.47 (+2.27%)
TSLA   174.80 (+0.44%)
NVDA   166.44 (+3.25%)
NIO   13.46 (+7.00%)
BABA   93.24 (+5.56%)
AMD   70.79 (+0.93%)
T   19.31 (+0.05%)
MU   55.14 (+2.45%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   85.37 (+0.44%)
DIS   92.89 (+0.80%)
AMC   6.39 (+5.62%)
PYPL   75.48 (+1.42%)
PFE   50.51 (+0.54%)
NFLX   311.25 (+0.92%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.97 (+1.23%)
AAPL   143.14 (+1.56%)
MSFT   246.59 (+0.91%)
META   115.76 (+1.61%)
GOOGL   94.11 (-0.87%)
AMZN   90.47 (+2.27%)
TSLA   174.80 (+0.44%)
NVDA   166.44 (+3.25%)
NIO   13.46 (+7.00%)
BABA   93.24 (+5.56%)
AMD   70.79 (+0.93%)
T   19.31 (+0.05%)
MU   55.14 (+2.45%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   85.37 (+0.44%)
DIS   92.89 (+0.80%)
AMC   6.39 (+5.62%)
PYPL   75.48 (+1.42%)
PFE   50.51 (+0.54%)
NFLX   311.25 (+0.92%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.97 (+1.23%)
AAPL   143.14 (+1.56%)
MSFT   246.59 (+0.91%)
META   115.76 (+1.61%)
GOOGL   94.11 (-0.87%)
AMZN   90.47 (+2.27%)
TSLA   174.80 (+0.44%)
NVDA   166.44 (+3.25%)
NIO   13.46 (+7.00%)
BABA   93.24 (+5.56%)
AMD   70.79 (+0.93%)
T   19.31 (+0.05%)
MU   55.14 (+2.45%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   85.37 (+0.44%)
DIS   92.89 (+0.80%)
AMC   6.39 (+5.62%)
PYPL   75.48 (+1.42%)
PFE   50.51 (+0.54%)
NFLX   311.25 (+0.92%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.97 (+1.23%)
AAPL   143.14 (+1.56%)
MSFT   246.59 (+0.91%)
META   115.76 (+1.61%)
GOOGL   94.11 (-0.87%)
AMZN   90.47 (+2.27%)
TSLA   174.80 (+0.44%)
NVDA   166.44 (+3.25%)
NIO   13.46 (+7.00%)
BABA   93.24 (+5.56%)
AMD   70.79 (+0.93%)
T   19.31 (+0.05%)
MU   55.14 (+2.45%)
CGC   3.22 (-0.62%)
F   13.18 (+0.61%)
GE   85.37 (+0.44%)
DIS   92.89 (+0.80%)
AMC   6.39 (+5.62%)
PYPL   75.48 (+1.42%)
PFE   50.51 (+0.54%)
NFLX   311.25 (+0.92%)
OTCMKTS:KHTRF

Knight Therapeutics - KHTRF Stock Forecast, Price & News

$3.81
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.81
$3.81
50-Day Range
$3.79
$4.06
52-Week Range
$3.66
$4.77
Volume
N/A
Average Volume
1,831 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.55
KHTRF stock logo

About Knight Therapeutics (OTCMKTS:KHTRF) Stock

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Stock News Headlines

Is Ardelyx is A Buy After Slip in Early 2022 (KHTRF)
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Knight to Present at Stifel Healthcare Conference
Knight Therapeutics reports Q4 results
Knight Therapeutics Inc (KHTRF)
Is Knight Therapeutics (TSE:GUD) Using Too Much Debt?
Knight Therapeutics Reports Third Quarter 2021
What Wall Street expects from Knight Therapeutics's earnings
Knight Therapeutics Reports Second Quarter 2021
See More Headlines
Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:KHTRF
CIK
N/A
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.55
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$5.40
Forecasted Upside/Downside
+71.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 53)
    BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
    Comp: $340.66k
  • Ms. Samira Sakhia BCom (Age 54)
    CA, CPA, MBA, Pres, CEO & Director
    Comp: $517.56k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens
    Global VP Commercial
  • Mr. Leopoldo Bosano
    Vice-Pres of Manufacturing & Operations
  • Ms. Daniela Marino
    Global VP of Legal & Compliance
  • Ms. Susan Caroline Emblem
    Global VP of HR
  • Ms. Jody Engel
    Sr. Director of Bus. Devel.













KHTRF Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KHTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KHTRF, but not buy additional shares or sell existing shares.
View KHTRF analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 1 year price objectives for Knight Therapeutics' stock. Their KHTRF share price forecasts range from $5.40 to $7.50. On average, they expect the company's stock price to reach $6.55 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price.
View analysts price targets for KHTRF
or view top-rated stocks among Wall Street analysts.

How have KHTRF shares performed in 2022?

Knight Therapeutics' stock was trading at $4.1605 at the beginning of 2022. Since then, KHTRF shares have decreased by 8.4% and is now trading at $3.81.
View the best growth stocks for 2022 here
.

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 118,700 shares, a decrease of 43.1% from the October 31st total of 208,500 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 1,187.0 days.
View Knight Therapeutics' Short Interest
.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $3.81.

How many employees does Knight Therapeutics have?

The company employs 660 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483.

This page (OTCMKTS:KHTRF) was last updated on 12/8/2022 by MarketBeat.com Staff